14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma.

      Journal of nuclear medicine : official publication, Society of Nuclear Medicine

      Tomography, X-Ray Computed, Gastrinoma, pathology, radionuclide imaging, radiotherapy, secondary, Heterocyclic Compounds, diagnostic use, pharmacokinetics, therapeutic use, Humans, Liver Neoplasms, radiography, Lymph Node Excision, Male, Metabolic Clearance Rate, Middle Aged, Pancreatic Neoplasms, surgery, Peptides, Cyclic, Radiopharmaceuticals, Receptors, Somatostatin, agonists, Recurrence, Tomography, Emission-Computed, Single-Photon

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid (DOTA)-lanreotide is a universal somatostatin (SST) receptor subtype ligand that binds to a large variety of human tumors. We report the case of a patient with metastatic gastrinoma who was treated with 90Y-DOTA-lanreotide. Before treatment, dosimetry with 111In-DOTA-lanreotide (150 MBq, 10 nmol) indicated a dose of 5.8 mGy/MBq for the recurrent abdominal gastrinoma, and a mean dose of approximately 1.0 mGy/MBq for liver metastases (i.e., 56 and approximately 10 mGy/MBq for 90Y-DOTA-lanreotide, respectively). After four infusions of 90Y-DOTA-lanreotide (each 1 GBq, approximately 30 nmol) over a 6-mo period, the 111In-DOTA-lanreotide scintigraphy of the liver had returned to a nearly normal condition and a remarkably decreased uptake by the recurrent gastrinoma was calculated (approximately 5 mGy/MBq for 90Y-DOTA-lanreotide). The imaging results were well-correlated with a 25% regression of the liver metastases as indicated by CT. Blood, urine and whole-body clearances of 111In-DOTA-lanreotide and 90Y-DOTA-lanreotide were very similar. The DOTA-lanreotide promises to be useful for functional tumor diagnosis (111In-DOTA-lanreotide) and receptor-mediated tumor radiotherapy (90Y-DOTA-lanreotide).

          Related collections

          Author and article information

          Journal
          9867148

          Comments

          Comment on this article